— Company Grants Teva a License to Market Generic VIVITROL Beginning in January 2027 — DUBLIN, Aug. 30, 2023 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. (“Teva”) to resolve the ongoing…
Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation
This post was originally published on this site